HMV Wealth Advisors LLC Sells 1,807 Shares of Johnson & Johnson (NYSE:JNJ)

HMV Wealth Advisors LLC cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 59.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,249 shares of the company's stock after selling 1,807 shares during the period. HMV Wealth Advisors LLC's holdings in Johnson & Johnson were worth $207,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson during the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson in the fourth quarter worth $33,000. Bernard Wealth Management Corp. acquired a new stake in Johnson & Johnson during the fourth quarter worth $36,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in Johnson & Johnson in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on JNJ shares. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Barclays cut their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Trading Up 0.2%

Shares of NYSE JNJ opened at $156.90 on Friday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a 50-day moving average of $153.84 and a two-hundred day moving average of $153.71. The company has a market cap of $377.52 billion, a PE ratio of 23.59, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson's payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.